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(two males, six females; mean age 38.9 \m=+-\10.4 years; 100.0 \m=+-\11.0 kg; mean body mass index 32.9 \m=+-\1.9 kg/m2). The groups were comparable for demographic data. Both serum insulin-like growth factor I (IGF-I) and IGF binding protein 3 (IGFBP-3) levels became significantly higher in the GH group (p = 0.001 and p = 0.014, respectively). Mean serum IGF-I levels increased from 29.0 \ m=+-\8. 19 nmol/l at randomization to 50.14 \m=+-\14.66 nmol/l after 2 weeks in the GH group, whereas the levels decreased from 34.25 \m=+-\ 10.26nmol/l to 27 .63 \m=+-\8.14 nmol/l in the placebo group. After two weeks, IGF-I and IGFBP-3 levels stabilized. In the first half of the study serum free triiodothyronine (T3) levels remained stable in the GH group, whereas a decrease was found in the placebo group. Mean serum free T3 level in the GH group was 5.59 \ m=+-\ 0.74pmol/l at randomization and 5 .69 \ m=+-\ 0.76 pmol/l after 2 weeks of treatment, whereas in the placebo group mean serum free T3 level decreased from 5 .89 \m=+-\1.04 pmol/l at randomization to 4 .61 \m=+-\ 0.78 pmol / l after two weeks (p = 0.033). In the same period, serum insulin levels increased in the GH group but remained unchanged in the placebo group. In the second half of the study these differences between both groups disappeared. However, in this period serum norepinephrine levels increased in the GH group and a trend in the same direction was seen for serum epinephrine levels. These changes were accompanied by an increase in both systolic and diastolic blood pressure following a consistent decrease in the previous weeks. Total weight loss was similar in both groups: 12.8 \m=+-\5.0 kg in the GH group versus 13.8 \ m=+-\4.0 kg in the placebo group. The decreases in fat mass, lean body mass and body water as measured by means of bioelectrical impedance analysis also were not different between the groups.
The nitrogen balance tended to be less negative in the GH group (mean nitrogen loss 3.37\m=+-\ (13, 14) . The body weight and impedance measurements were performed after voiding the bladder.
After the 8-week treatment period the patients were instructed to return to a normal diet in a 2-week period.
In the first week one-third of the very low calorie diet was replaced by a normal meal, in the second week another normal meal was added and thereafter the very low calorie diet was completely replaced by a normal diet.
Within the first week of treatment three patients (one using GH and two using placebo) dropped-out because of intolerance to the very low calorie diet or reasons not related to the study. In the second half of the study two more patients (both using GH) dropped out because they could no longer be motivated to finish the study protocol. The results of these five patients were not included in the statistical analysis. The remaining 15 patients (seven using GH and eight using placebo) completed the study period and their results were evaluated statistically. The demographic data of the patients are shown in Table 1 .
Assays
Urinary nitrogen was measured using photometry as published previously (15) . Serum insulin was measured using an Insik-5 radioimmunoassay (Sorin Biomedica, Both serum epinephrine and serum norepinephrine tended to increase in the GH group, mainly in the second half of the study, whereas the catecholamine levels in the placebo group decreased (p = 0.088 and = 0.075, respectively; trend analysis) (Fig. 6) . For norepinephrine the differences between the groups even became significant after 6 (Fig. 7) . Heart rate remained stable in both groups. 
Discussion
Considering the effect on the serum levels of IGF-I, which increased to levels in the supraphysiological range despite the severe calorie restriction, the GH dose of 6 U/day as used in this study seems to be effective. This dose, being lower than those used in other studies and leading to a smaller increase in IGF-I levels, was chosen in order to minimize the appearance of side effects and to optimalize patient compliance (9-11).
Nevertheless, a considerable number of the patients complained of side effects (peripheral edema) and in three of them we had to reduce the dose of GH, which did not lead to changes in mean serum IGF-I levels. In concordance with the increase in IGF-I levels, serum IGFBP-3 levels also increased in the first two study weeks and remained elevated during the remaining 6 weeks of the study. It is well known that fasting as well as protein restriction cause a decrease of IGFBP-3 levels (17) (18) (19) . This effect has been reversed completely by the GH administration and subsequent increase in IGF-I levels.
The combination therapy of the very low calorie diet and physical exercise program resulted in a consider¬ able amount of weight loss, comparable to previous results (5, 6) . Growth (20) (21) (22) (23) (24) (25) (26) . Growth hormone is known to enhance the peripheral con¬ version of T4 into T3 and therefore able to antagonize the free T3 lowering effect of calorie restriction (27) (10, 11, (28) (29) (30) . Obviously this effect is more pronounced than the insulin lowering effect of weight reduction itself, altogether resulting in increased serum insulin levels (31) (32) (33) (34) . It is of interest to notice that the effect on free T3 levels and on insulin levels disappeared in the second half of the study, despite the continued high IGF-I levels. This finding is in concordance with previous results and suggests the development of resistance to the effects of GH (11) Surprisingly, the serum levels of both epinephrine and norepinephrine tended to increase in the GH group in the second half of the study, resulting in the slight increase in blood pressure in the last study weeks.
On the other hand, no effect on heart rate was found. This discrepancy can be explained by the greater, even significant, increase in norepinephrine levels compared to the smaller increase in epinephrine levels (38) . The 
